Double-blind, placebo-controlled, single and multiple ascending dose phase I trial evaluating the safety, tolerability and pharmacokinetics of CCX 872 in volunteers

Trial Profile

Double-blind, placebo-controlled, single and multiple ascending dose phase I trial evaluating the safety, tolerability and pharmacokinetics of CCX 872 in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs CCX 872 (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 20 Apr 2015 According to ChemoCentryx media release, results will be presented at the American Association for Cancer Research (AACR).
    • 12 Mar 2015 Status changed from active, no longer recruiting to completed, according to a ChemoCentryx media release.
    • 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top